General Information

Government Type

State Agency

Entity

Department of Health and Human Services (DHHS)

Public Body

Pharmacy and Therapeutics Committee

Notice Information

Add Notice to Calendar

Notice Title

Pharmacy and Therapeutics Committee Meeting

Notice Tags

Medicaid, Pharmacies

Notice Type(s)

Meeting

Event Start Date & Time

April 16, 2015 07:00 AM

Event End Date & Time

April 16, 2015 08:30 AM

Event Deadline Date & Time

04/09/15 06:00 PM

Description/Agenda

AGENDA Utah Department of Health Pharmacy and Therapeutics Committee Thursday, April 16, 2015 7:00 a.m. to 8:30 a.m. Cannon Health Building Room 128 Please note that persons who wish to address the P&T Committee may contact Lisa V. Hunt (lvhunt@utah.gov) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints 1) Welcome and Introductions - Kort Delost, R.Ph., Chair a) Review and Approval of Minutes b) Update on PDL Administration - Lisa V. Hunt, R.Ph. c) Housekeeping d) Provider Testing Announcement - Melanie Wallentine 2) DUR Board Update - Robyn Seely, PharmD 3) Annual Open Public Meetings Act Training - Tony Patterson, J.D., A.A.G. a) Annual Chairperson Election - Lisa V. Hunt, R.Ph. b) New Member Training Material - Lisa V. Hunt, R.Ph. 4) April Review: a) Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors -Melissa Archer, PharmD Agents to include: Canagliflozin, Canagliflozin/Metformin, Dapagliflozin, Dapagliflozin/Metformin, Empagliflozin, similar and related products i) Other States Report - Lisa V. Hunt, R.Ph. ii) Public Comment (1) Julie L. McDavitt, Pharm.D., Senior Associate Director, Health Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals, Inc. (2) Laura M. Litzenberger, PharmD, MBA, Principal Liaison, Health Economics and Outcomes Research Field Jansen Scientific Affairs, LLC (3) Sushma Patel, PharmD, AstraZeneca Regional Clinical Account Director iii) Board Discussion/Questions iv) Board Action 5) Next Meeting May 21 2015 (Update: Hepatitis C Combination Agents & Agents used to treat Angina) 6) Adjourned - Kort Delost, R. Ph., Chair Public comment that responds to the materials presented by the College of Pharmacy @University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the University of Utah, College of Pharmacy, and are posted in advance on the P&T Committee website. Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to: Dr. Gary Oderda College of Pharmacy 30 South 2000 East SLC, UT 84112-5820 All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search. Tentative 2015 Pharmacy & Therapeutics Committee Schedule Month Topic Agents 4/16/15 Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Canagliflozin, Canagliflozin/Metformin, Dapagliflozin, Dapagliflozin/Metformin, Empagliflozin, Empagliflozin/Linagliptin Annual Training Annual Training 5/21/15 Update: Hepatitis C Combination Agents Ledipasvir/Sofosbuvir (Harvoni) and Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir (Viekira Pak) Agents used to treat Angina Nitroglycerin, Ranolazine, Amyl Nitrite, Isosorbide Dinitrate, Isosorbide Mononitrate 6/18/15 No Meeting Annual Meeting 7/16/15 Antiretroviral, Protease Inhibitors Atazanavir, Atazanavir/Cobicistat, Darunavir, Fosamprenavir, Indinavir, Lopinavir/Ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir 8/20/15 Agents used to Treat Irritable Bowel Syndrome (IBS) Alosetron, Linaclotide, Lubiprostone Bowel Cleansing/Prep Agents Polyethylene Glycol 3350, Polyethylene Glycol-Electrolyte Solution, Sodium Picosulfate/Magnesium Oxide/Citric Acid, Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate, Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate/Polyethylene Glycol-Electrolyte Solution 9/17/15 Immune Globulin Agents Bivigam, Carimune NF, Flebogamma, Flebogamma DIF, GamaSTAN S/D, Gammagard, Gammagard S/D, Gammagard S/D Less IgA, Gammaked, Gammaplex, Gamunex-C, Hizentra, Hizentra 20%, Octagam, Privigen 10/15/15 Ophthalmic Beta-Adrenergic Antagonists Betaxolol, Carteolol, Levobunolol, Metipranolol, Timolol and all combination agents Ophthalmic Cholinergic Agonists Acetylcholine, Carbachol, Pilocarpine 11/19/15 Ophthalmic Muscarinic Antagonists Atropine, Scopolamine, Homatropine, Cyclopentolate, Tropicamide Ophthalmic Miscellaneous Agents TBD 12/17/15 Beta-Lactams/Clavulanate Combos Amoxicillin, Amoxicillin/Clavulanate, Ampicillin, Ampicillin/Sulbactam, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Penicillin, Piperacillin, Piperacillin/Tazobactam, Ticarcillin/Clavulanate

Notice of Special Accommodations (ADA)

NOTICE OF SPECIAL ACCOMMODATION DURING PUBLIC MEETINGS In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Lisa Hunt at 801-538-6317.

Notice of Electronic or Telephone Participation

N/A

Meeting Information

Meeting Location

288 North 1460 West
Cannon Health Building, Room 128
Salt Lake City, 84116
Show in Apple Maps Show in Google Maps

Contact Name

Ngan Huynh

Contact Email

nganhuynh@utah.gov

Contact Phone

801-538-6155

Notice Posting Details

Notice Posted On

April 02, 2015 02:40 PM

Notice Last Edited On

May 08, 2015 04:09 PM

Deadline Date

April 9, 2015 06:00 PM

Subscribe by Email

Subscription options will send you alerts regarding future notices posted by this Body.